Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets [Yahoo! Finance]
Pyxis Oncology, Inc. (PYXS)
Company Research
Source: Yahoo! Finance
clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced the appointment of Alex Kane, MBA, as Senior Vice President, Investor Relations & Capital Markets, effective immediately. Mr. Kane brings 20 years of experience and a proven track record in investor relations, strategic communications, and equity capital markets across the life sciences sector. He joins Pyxis Oncology from Guggenheim Securities, where he served as Vice President of Equity Capital Markets, advising biotechnology clients on financing strategies and equity transactions. Previously, Mr. Kane held senior investor relations and communications roles at Praxis Precision Medicines and PTC Therapeutics, successfully managing IPOs, secondary offerings, and long-term investor engagement. Earlier in his career, he held leadership positions at W2O Group, NASDAQ, and Thomson Reuters, where he advised public and private life sciences companies on capital ma
Show less
Read more
Impact Snapshot
Event Time:
PYXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PYXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PYXS alerts
High impacting Pyxis Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
PYXS
News
- Pyxis Oncology (NASDAQ:PYXS) had its "overweight" rating reaffirmed by analysts at Stephens.MarketBeat
- Pyxis Oncology (NASDAQ:PYXS) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- Pyxis Oncology (NASDAQ:PYXS) was given a new $7.00 price target on by analysts at Guggenheim.MarketBeat
- Pyxis Oncology to Participate in Upcoming Investor ConferencesGlobeNewswire
- Pyxis Oncology (NASDAQ:PYXS) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $9.00 price target on the stock.MarketBeat
PYXS
Earnings
- 8/14/25 - Beat
PYXS
Sec Filings
- 11/26/25 - Form S-3
- 11/3/25 - Form 10-Q
- 11/3/25 - Form 8-K
- PYXS's page on the SEC website